NOV 17, 202654 MINS READ
Croscarmellose Sodium is a cross-linked polymer derived from carboxymethylcellulose sodium, engineered to provide superior disintegration performance in compacted oral dosage forms 39. The cross-linking introduces three-dimensional network structures that resist dissolution while enabling rapid water uptake and volumetric expansion. Upon contact with aqueous media, the polymer chains undergo rapid hydration, generating localized swelling pressures (typically 10–50 kPa depending on cross-link density) that mechanically disrupt the tablet matrix 12.
The disintegration mechanism operates through three concurrent pathways:
The degree of substitution (DS) for carboxymethyl groups typically ranges from 0.6 to 0.95 per anhydroglucose unit, with higher DS values correlating with faster hydration kinetics but reduced mechanical stability during compression 3. The cross-linking density, controlled during synthesis via esterification or ether bond formation, must be optimized to balance swelling capacity (typically 400–800% volume increase) against premature gel formation that could retard drug release 9.
Conventional pharmaceutical excipient guidelines recommend Croscarmellose Sodium at 0.5–5% w/w with median particle sizes of 30–50 μm 39. However, systematic investigations reveal that coarser particles (≥56 μm) at elevated concentrations (≥4% w/w) deliver superior disintegration kinetics across diverse active pharmaceutical ingredients (APIs) and manufacturing processes 128.
Patent literature establishes critical particle size thresholds for enhanced performance 1213:
Disintegration time correlates inversely with particle size above 56 μm: tablets containing 6% w/w Croscarmellose Sodium at d₅₀ = 86 μm disintegrate in 12–18 seconds (USP <701> apparatus, 37°C deionized water), compared to 25–35 seconds for 50 μm material at equivalent concentration 18. This phenomenon arises from increased interparticle void volume in coarser grades, facilitating faster water ingress before significant gel layer formation 2.
Elevated Croscarmellose Sodium levels (≥4% w/w) are essential for APIs with poor wettability or high-dose formulations (>200 mg API per tablet) 128:
Upper concentration limits (typically ≤20% w/w for immediate release, ≤30% w/w for suspension tablets) prevent excessive friability (<0.8% mass loss, USP <1216>) and maintain tablet hardness (50–100 N) 124.
Croscarmellose Sodium functions optimally when paired with complementary excipients that balance mechanical strength, flow properties, and disintegration kinetics 5614:
The distribution of Croscarmellose Sodium within the formulation architecture significantly impacts disintegration pathways 3914:
Croscarmellose Sodium demonstrates versatility across tabletting technologies, though process-specific adjustments are necessary 1813:
Croscarmellose Sodium serves as the disintegrant of choice for APIs requiring fast onset of action (Tmax <30 minutes) 1813:
ODT formulations demand disintegration within 30 seconds in the oral cavity (USP <701> modified method, 6–10 mL saliva simulant at 37°C) while maintaining mechanical robustness during packaging and handling 101112:
Contrary to conventional wisdom, Croscarmellose Sodium enables extended-release profiles when combined with pH-modulating agents and hydrophobic matrices 47:
Palatability and ease of administration drive Croscarmellose Sodium selection in companion animal formulations 6:
Croscarmellose Sodium must comply with pharmacopeial monographs (USP-NF, Ph. Eur., JP) that define critical quality attributes 3910:
Critical process parameters (CPPs) for Croscarmellose Sodium-containing formulations require validation per ICH
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| FMC CORPORATION | Immediate-release tablets for analgesics, cardiovascular agents, and CNS drugs requiring rapid onset (Tmax <30 minutes); suspension tablets for pediatric/geriatric populations; direct compression and wet granulation manufacturing processes. | Croscarmellose Sodium (Coarse Grade) | Median particle size ≥56 μm at ≥4% w/w concentration achieves tablet disintegration in <20 seconds, with optimized performance at 70-100 μm delivering 12-18 second disintegration times compared to 25-35 seconds for conventional 50 μm grades. |
| FMC CORPORATION | Orally disintegrating tablets (ODTs) for pediatric and geriatric patients requiring disintegration within 30 seconds in oral cavity; taste-masking coating systems; low-dose API formulations requiring uniform content distribution. | Fine Particle Croscarmellose Sodium | Median particle size 5-36 μm with specific surface area ≥0.3 m²/g at 0.5-2% w/w enables rapid wicking and disintegration in 8-15 seconds for orally disintegrating tablets while maintaining mechanical robustness (friability <1.0%). |
| ORION CORPORATION | Parkinson's disease treatment formulations requiring enhanced release rates of poorly soluble catechol-O-methyltransferase (COMT) inhibitors; high-dose tablets (>200 mg API) with challenging wettability profiles. | Entacapone/Nitecapone Tablets | Croscarmellose sodium at 10-14% w/w concentration overcomes hydrophobic crystalline nature of catechol derivatives (log P 2.5-3.2), achieving >80% dissolution within 15 minutes for immediate therapeutic effect. |
| SHIONOGI & CO. LTD. | Sustained-release oral solid dosage forms requiring controlled disintegration and pH-modulated release profiles; drugs requiring protection from gastric degradation with targeted intestinal absorption. | Extended Release Formulation System | Croscarmellose sodium (5-15% w/w) combined with sodium/potassium carbonate (5-20% w/w) and magnesium oxide (5-15% w/w) creates alkaline microenvironment (pH 8-10) that moderates swelling, extending drug release over 8-12 hours with pulsatile intestinal delivery. |
| Sumitomo Dainippon Pharma Co. Ltd. | Digestive disease treatments, psychoneurological disorder medications, and urinary disease therapies requiring rapid dissolution and consistent bioavailability; formulations containing moisture-sensitive APIs with 5-20% w/w drug loading. | Solid Oral Dosage Forms with Water-Soluble Excipients | Croscarmellose sodium (1-10% w/w) combined with mannitol matrix and water-soluble polymer binders provides excellent dissolution properties while maintaining tablet integrity (tensile strength 1.5-2.5 MPa) for prokinetic and neurological agents. |